Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the E fficacy and D urability of I nitial C ombination T herapy for T ype 2 D iabetes ( EDICT ): a randomized trial
Diabetes Obesity and Metabolism2014Vol. 17(3), pp. 268–275
Citations Over TimeTop 10% of 2014 papers
M. A. Abdul‐Ghani, Curtiss Puckett, Curtis Triplitt, David Maggs, John M. Adams, Eugênio Cersósimo, Ralph A. DeFronzo
Abstract
The results of this exploratory study show that combination therapy with metformin/pioglitazone/exenatide in patients with newly diagnosed T2DM is more effective and results in fewer hypoglycaemic events than sequential add-on therapy with metformin, sulfonylurea and then basal insulin.
Related Papers
- → Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes(2004)1,338 cited
- → 2-Year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with Type 2 diabetes(2008)29 cited
- → Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea(2006)29 cited
- → Abstract #20: Effects of Exenatide (Synthetic Exendin-4) on Glucose Control and Safety in Patients with Type 2 Diabetes Treated with Metformin, a Sulfonylurea, or Both: An Ongoing, Open-Label Phase 3 Trial(2004)5 cited
- → Clinical characteristics and outcomes in patients with type 2 diabetes adding insulin glargine to exenatide or exenatide to insulin glargine in a US managed care setting(2011)